The benefits and harms of adjuvant chemotherapy for non-small cell lung cancer in patients with major comorbidities: A simulation study.

Amanda Leiter Chung Yin KongMichael K GouldMinal S KaleRajwanth R VeluswamyCardinale B SmithGrace MhangoBrian Z HuangJuan P WisniveskyKeith Sigel

Published in: PloS one (2022)

Older, multimorbid patients may derive QALY gains from adjuvant chemotherapy after NSCLC surgery. These results help extend existing clinical trial data to specific unstudied, high-risk populations and may reduce the uncertainty regarding adjuvant chemotherapy use in these patients.

Keyphrases

clinical trial
end stage renal disease
ejection fraction
newly diagnosed
small cell lung cancer
prognostic factors
physical activity
acute coronary syndrome
atrial fibrillation
machine learning
open label
tyrosine kinase
patient reported
middle aged